Spectrum Announces Completion of
Selected Abstract
Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Benign Prostatic Hypertrophy.
* Enrollment was completed ahead of schedule by more than four months * This is a multicenter, placebo controlled, randomized study in 144 patients with BPH IRVINE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that the Company has achieved complete ... November 21, 2005; PR Newswire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients with Hormone Dependent Prostate Cancer.
2.
Spectrum Announces Completion of Patient Enrollment in Ozarelix Phase II Trial in Patients With Benign Prostatic Hypertrophy.
3.
Spectrum Announces Completion Of Target Enrollment In Ozarelix Phase 2b Trial In Benign Prostate Hypertrophy.
|
